読み込み中
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
前日終値
$5.78
+$0.09 · +1.58%
日中の時刻はETです。市場データは遅延する場合があります。
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
日中レンジ
現在 $5.78
52週レンジ
現在 $5.78
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
49
適正価値
センチメント
53
まちまち
リスク
64
高リスク
モメンタム
21
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
日中レンジ
現在 $5.78
52週レンジ
現在 $5.78
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（EUR） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.75億 EUR | 1.7億 EUR | 1.54億 EUR | 3.61億 EUR | 3.48億 EUR |
| 売上原価 | 1.07億 EUR | 9853.8万 EUR | 1.01億 EUR | 3.24億 EUR | 1.88億 EUR |
| 粗利益 | 6751.9万 EUR | 7104万 EUR | 5283.7万 EUR | 3686.2万 EUR | 1.6億 EUR |
| 研究開発 | 8530.3万 EUR | 7414.3万 EUR | 5989.4万 EUR | 1.05億 EUR | 1.73億 EUR |
| 販売・一般管理 | 7467.8万 EUR | 9510.6万 EUR | 9655.1万 EUR | 5758.2万 EUR | 7124.9万 EUR |
| 営業費用 | 1.49億 EUR | 5771万 EUR | 1.35億 EUR | 1.5億 EUR | 2.22億 EUR |
| 受取利息 | 180.3万 EUR | 236.2万 EUR | 121万 EUR | 26万 EUR | 24.9万 EUR |
| 支払利息 | 4189.8万 EUR | 2398.4万 EUR | 2332.5万 EUR | 1905.4万 EUR | 1696.3万 EUR |
| 減価償却費と償却費 | 2175万 EUR | 1958.6万 EUR | 1758.4万 EUR | 2103.6万 EUR | 1428.1万 EUR |
| 営業利益 | −8163.1万 EUR | 1333万 EUR | −8208.7万 EUR | −1.13億 EUR | −6139.1万 EUR |
| 純利益 | −1.15億 EUR | −1224.7万 EUR | −1.01億 EUR | −1.43億 EUR | −7342.5万 EUR |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$11.00
上昇余地（90.31%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
